Retrospective Study
Copyright ©The Author(s) 2021.
World J Hepatol. Dec 27, 2021; 13(12): 2081-2103
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2081
Table 3 Risk factors for biliary strictures: Categorical factors
Variable
Biliary strictures
OR
CI
P value1
No stricture (n = 109)
Stricture (n = 60)
95% LCL
95% UCL
n, Row %
n, Row %
Etiology of cirrhosisHCV95 (64.2)53 (35.8)0.1422
Isolated HBV5 (100)0 (0)
Combined HCV & HBV1 (25)3 (75)
Causes other than viral hepatitis8 (66.7)4 (33.3)
Donors’ genderMale90 (63.8)51 (36.2)0.80.42.00.684
Female19 (67.9)9 (32.1)
Recipients’ genderMale96 (64)54 (36)0.80.32.30.704
Female13 (68.4)6 (31.6)
HCV PCR viremia prior to transplantationNegative20 (60.6)13 (39.4)0.7683
Below 200000 IU41 (69.5)18 (30.5)
200000 to 2 million44 (63.8)25 (36.2)
More than 2 million4 (50)4 (50)
Antiviral treatment prior to transplantation-92 (66.7)46 (33.3)1.60.73.60.214
+17 (54.8)14 (45.2)
Hepatocellular carcinoma-71 (65.1)38 (34.9)1.10.62.10.815
+38 (63.3)22 (36.7)
Arterial complications-102 (65.8)53 (34.2)1.90.65.80.2552
+7 (50)7 (50)
Number of anastomosesOne 70 (64.2)39 (35.8)0.9103
Two 37 (64.9)20 (35.1)
Three2 (66.7)1 (33.3)
Number of ducts1 Duct50 (64.1)28 (35.9)0.8573
2 Ducts52 (66.7)26 (33.3)
3 Ducts6 (50)6 (50)
4 Ducts1 (100)0 (0)
Number of stentsNil5 (71.4)2 (28.6)0.5783
1 Stent43 (60.6)28 (39.4)
2 Stents53 (67.1)26 (32.9)
3 Stents7 (63.6)4 (36.4)
4 Stents1 (100)0 (0)
ImmunosuppressantTacrolimus81 (68.6)37 (31.4)1.80.93.50.087
Cyclosporine 28 (54.9)23 (45.1)
Biliary leakage-80 (70.2)34 (29.8)2.11.14.10.026
+29 (52.7)26 (47.3)
Biliary infection-62 (86.1)10 (13.9)6.63.014.4< 0.001
+47 (48.5)50 (51.5)
Frequency of biliary infectionNil62 (86.1)10 (13.9)< 0.0013
1-2 Episodes45 (53.6)39 (46.4)
≥ 3 Episodes2 (15.4)11 (84.6)
Early biliary infection-64 (82.1)14 (17.9)4.72.39.5< 0.001
+45 (49.5)46 (50.5)
Chronic graft rejection-99 (69.7)43 (30.3)3.91.79.20.001
+10 (37)17 (63)
Recurrent HCV-87 (68)41 (32)1.80.93.80.096
+22 (53.7)19 (46.3)